This image is not available for purchase in your country.

Herceptin breast cancer drug

Herceptin breast cancer drug

A617/0140

Rights Managed

This image is not available for purchase in your country.

Please contact your Account Manager if you have any query.

Credit

DR TIM EVANS / SCIENCE PHOTO LIBRARY DR TIM EVANS / SCIENCE PHOTO LIBRARY

Caption

Herceptin breast cancer drug, molecular model. Herceptin (trastuzumab) is a monoclonal antibody comprising two protein chains (blue and pink). It works by binding to and blocking the HER2 receptor, which is found on some breast cancer cells. HER2 (human epidermal growth factor receptor 2) overabundance makes cancer cells faster-growing and more likely to spread. Herceptin treatment greatly improves the chances of curing the cancer. Around 20% of breast cancers have HER2 over-expression, and are thus viable targets for the drug. In the UK in 2005, it was announced that all women with early breast cancer would be tested to see if their tumours would be receptive to Herceptin therapy.

Release details

Model release not required. Property release not required.

 {{ i.shot_duration ? i.shot_duration + ' ' : '' }}{{ i.shot_uhd ? '4K ' : i.hires ? 'HD ' : '' }}{{ i.spl_number }} R{{ i.license }}

  • Add to board
  • Similar {{ mediaType(i) }}